Key result
Diabetic cardiomyopathy is driven by insulin resistance and hyperglycemia, leading to a cascade of pathophysiological events that culminate in cardiac remodeling and clinical heart failure.
This review provides a concise overview of the pathophysiological mechanisms underlying diabetic cardiomyopathy and outlines current potential therapeutic strategies.
Answers are grounded in this paper and cite their sources.
Supports mechanistic research on diabetic cardiomyopathy; leaves open targeted therapies pending prospective trials.
Diabetic cardiomyopathy (DCM) is a significant complication of diabetes mellitus characterized by gradually failing heart with detrimental cardiac remodelings, such as fibrosis and diastolic and systolic dysfunction, which is not directly attributable to coronary artery disease. Insulin resistance and resulting hyperglycemia is the main trigger involved in the initiation of diabetic cardiomyopathy. There is a constellation of many pathophysiological events, such as lipotoxicity, oxidative stress, inflammation, inappropriate activation of the renin-angiotensin-aldosterone system, dysfunctional immune modulation promoting increased rate of cardiac cell injury, apoptosis, and necrosis, which ultimately culminates into interstitial fibrosis, cardiac stiffness, diastolic dysfunction, initially, and later systolic dysfunction too. These events finally lead to clinical heart failure of DCM. Herein, The pathophysiology of DCM is briefly discussed. Furthermore, potential therapeutic strategies currently used for DCM are also briefly mentioned.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2020) conducted a review in Diabetic cardiomyopathy. Diabetic cardiomyopathy is driven by insulin resistance and hyperglycemia, leading to a cascade of pathophysiological events that culminate in cardiac remodeling and clinical heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: